Cytovation AS, a biotechnology company, develops peptide products for the treatment of cutaneous warts caused by human papilloma virus (HPV). The company's product CyPep-1 consists of 27 amino acids, targets HPV diseased cells, and kills the wart cells by disrupting the cell membrane and creating an immune response through the release of antigens. CyPep-1 has world-wide patent protection across the USA, Europe, Japan, and China. The company was founded in 2001 and is based in Bergen, Norway.